← Back to Clinical Trials
Recruiting NCT04721418

NCT04721418 Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04721418
Status Recruiting
Phase
Sponsor Yale University
Condition Cocaine Use Disorder
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2021-07-20
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
11C-UCB-J

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2021-07-20 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.

Eligibility Criteria

Inclusion Criteria: * Age 21-60 years * Physically healthy by medical history, physical, neurological, ECG and laboratory examinations * For females, a negative serum pregnancy test * For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use * For HC: Negative urine toxicology Exclusion Criteria: * DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine * A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5) * A history of significant and/or uncontrolled medical or neurological illness * Current use of psychotropic and/or potentially psychoactive prescription medications * Medical contraindications to MRI procedure

Contact & Investigator

Central Contact

Marcella Mignosa, MD

✉ marcella.mignosa@yale.edu

📞 203 974 7557

Principal Investigator

Gustavo Angarita, MD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT04721418 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 60 Years, studying Cocaine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04721418 currently recruiting?

Yes, NCT04721418 is actively recruiting participants. Contact the research team at marcella.mignosa@yale.edu for enrollment information.

Where is the NCT04721418 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT04721418 clinical trial?

NCT04721418 is sponsored by Yale University. The principal investigator is Gustavo Angarita, MD at Yale University. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology